Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Background:

• Anti-vascular endothelial growth factor (anti-VEGF) therapy is widely used in oncology.
• Proteinuria is a known side effect of anti-VEGF agents.
• Current management often focuses on nephrotic-range proteinuria or renal insufficiency.

Purpose of the Study:

• To investigate the significance of proteinuria in patients receiving anti-VEGF therapy.
• To assess the correlation between low-grade proteinuria and underlying renal histology.
• To highlight the need for closer monitoring of renal function in these patients.

Main Methods:

• Retrospective analysis of 78 patients treated with anti-VEGF therapy.
• Evaluation of proteinuria levels and renal function.
• Correlation of proteinuria with histological findings in renal biopsies (where available).

Main Results:

• Proteinuria developed in a significant proportion of patients undergoing anti-VEGF treatment.
• Even weak proteinuria, without overt renal insufficiency, was associated with serious histological renal disease in some cases.
• This suggests that proteinuria is an important marker of anti-VEGF-induced nephrotoxicity.

Conclusions:

• Proteinuria induced by anti-VEGF therapy warrants careful evaluation, irrespective of its severity.
• Early recognition of proteinuria may help identify patients with significant underlying renal pathology.
• Oncologists and nephrologists should consider proactive renal monitoring for all patients on anti-VEGF treatment.